UNITED STATES
                         SECURITIES EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                  FORM 10KSB/A

                Annual Report Pursuant to Section 13 or 15 (d) of
                       the Securities Exchange Act of 1934

                           ENHANCE LIFESCIENCES INC.

             (Exact name of registrant as specified in its charter)



             DELAWARE                            13-4044714
             --------                            ----------
     (State or other jurisdiction             (I.R.S. Employer
     of incorporation or organization)        Identification No.)

     1285 Avenue of the Americas
     35th Floor
     New York, NY,                                 10019
     ----------------------------------            -----
  (Address of principal executive offices)       (Zip Code)


Registrant's telephone number             (212) 561 1716
                                          --------------


       Securities to be registered pursuant to Section 12(g) of the Act:

                         VOTING COMMON STOCK 20,000,000

Check here whether the issuer (1) has filed all reports required to be filed by
Sections 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding
12 months (or for such shorter period that the registrant was required to file
such reports), and (2) has been subject to such filing requirements for the past
90 days.

                                    YES X NO
As of November 17, 2003, the following shares of the Registrant's common stock
were issued and outstanding:

Voting common stock 20,000,000

Traditional Small Business Disclosure
(check one): Yes X No



<PAGE>



                                     PART I

ITEM 1. DESCRIPTION OF THE BUSINESS

HISTORY AND ORGANIZATION

ENHANCE LIFESCIENCES INC., (the "Company"), a developmental stage company, was
organized on April 24, 1997 under the laws of the State of Delaware, having the
stated purpose of engaging in any lawful act or activity for which corporations
may be organized.

The Company was formed to enter the telecommunications industry and provide
international telephone interface service. The company sought to provide two
types of service to consumers: call re-routing via a cheaper international
carrier and telephone calling card service. Its business plan was to install
communication equipment to re-route calls directly, purchasing time from an
international call carrier. The Company's original business plan failed and the
company sought to merge or be acquired by another corporation.

During the quarter to 31st October 2002, the company was introduced to Enhance
Lifesciences Limited, a UK corporation, prior to this transaction completing the
Company changed its name to Enhance Lifesciences Inc.

On September 10, 2002, they entered into an Acquisition Agreement to acquire 2
shares of Ordinary stock, GPB 1.0 par value being one hundred (100%) percent of
the issued and outstanding Ordinary shares, of Enhance Lifesciences Limited
(ELSL), a company incorporated under the laws of England. The transaction
completed on the 17th December 2002. The acquisition is considered a reverse
merger and will be accounted for on this basis (see Notes to the Accounts).


The aggregate purchase price paid by the Company for the ELSL common shares was
17,000,000 post-reverse split shares of voting common stock of Enhance Life
Sciences Inc.(ELSI), $0.001 par value. These shares will be issued to the
sellers of the ELSL shares subsequent to a 2 for 1 reverse split of the voting
common stock by the Company of its voting common stock.

There was no material relationship between the Company and ELSL prior to the
acquisition by the company of the ELSL shares. Subsequent to the acquisition of
the ELSL shares, the Company intends to enter the pharmaceutical industry, in
particular the emerging sector of lifestyle drugs. Enhance Life Sciences is a
pharmaceutical company with a primary focus on the development of lifestyle drug
products. ELSL aim to manage the convergence of groundbreaking science to create
strong, commercially successful products in international markets. The products
which Enhance Life Sciences seeks to develop will be used to treat a range of
lifestyle ailments, from sexual dysfunction to hair loss.

Subsequent to the year end of January 31, 2003, on April 29th 2003, the
company's 20,000,000 issued and outstanding common stock was acquired by Becor
Communications Inc, a Delaware corporation, whereby Becor Communications Inc,
now called Enhance Biotech Inc, became the Company's sole stockholder.

It is the Company's intention to continue filing its statutory filings with the
Securities and Exchange Commission.

ITEM 2. DESCRIPTION OF PROPERTY

The company's administrative offices are located at 1285 Avenue of the Americas,
35th Floor, New York, NY, 10019 and 29 Harley St, London, UK.

ITEM 3. LEGAL PROCEEDINGS

There are no legal proceedings are pending at this time.

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

The Security Holders were asked to vote on the acquisition of Enhance
Lifesciences Limited, and a majority of 100% voted for the transaction.


<PAGE>


                                     PART II

ITEM 5. MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS

The Company is not aware of any quotations for its common stock, now or at any
time within the past two years. As of January 31, 2003, there were approximately
11 holders of record of the issued and outstanding shares of Issuer's common
stock. Issuer has never paid a dividend on its outstanding equity. The Company
currently has no established public trading market for its common stock.



<PAGE>



ITEM 6. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS

Enhance Lifesciences Inc, or ("the Company") is an emerging pharmaceutical
company wholly owned by Enhance Biotech Inc, developing an innovative portfolio
of products for the rapidly growing lifestyle drugs market. The company has six
key lifestyle product areas amongst which some are potentially blockbuster
status solutions to the needs of their particular conditions.

The market is recognised as growing rapidly to some $29 billion in the years to
2007 as the table below demonstrates. Added to this is the industry's spend on
lifestyle drug development in the last ten years which exceed $20 billion, each
of which demonstrates the attractive potential of this part of the global
pharmaceutical market place. In spite of this concentration on development for
the market, and the notable success of blockbuster drugs such as Viagra and
Xenical, relatively few successful solutions to the conditions recognised in
lifestyle category have actually reached market as yet. In addition there are
some conditions where very little work has been accomplished in spite of the
potential global market opportunity. Enhance's portfolio focuses upon six key
areas of the lifestyle market and in some cases is developing platform products
with potential ongoing development for related indications too. The key areas
are; sexual dysfunction, anti-ageing, depression, cellulite, in vitro
fertilisation and arthritis. A recent Reuters report on the lifestyle drug
sector demonstrates clearly the potential for successful participants in this
area as well as highlighting specifically some of the key areas in which the
Enhance portfolio will be active.

Enhance Biotech has and will continue to acquire and develop drug candidates
from the main lifestyle disorder categories. Through licensing in early to mid
stage products we will use our expertise and an established network of
development and commercialisation partners to build long term value in to the
products for the company and shareholders.

By selecting the products acquired to be at varying development stages we are
able to take full benefit from the earliest opportunities to market while
looking to a strong product pipeline going forward. Amongst our five key areas
of development we have a number which while capable of achieving market
readiness with the initial science already have the ability to generate a second
phase of products offering still greater benefit and flexibility for the
lifestyle environment.

In addition to the pursuit of innovation and new development Enhance will make
use of reformulation technology in partnership with specialist, internationally
recognised technology houses to assist in meeting the needs of some lifestyle
conditions.

Revenue will be developed through a mixture of marketing license agreements with
major pharmaceutical companies where penetration of the end market for the
product justifies it and direct marketing of the products through Enhance
Biotech distribution channels and potentially direct via the internet.

To achieve this strategy the company has created and will continue to build on a
strong management, experienced in building science and technology based
businesses through partnership and licensing structures. An independent
scientific board will be appointed in addition to a supporting scientific and
commercial team. However the Enhance core business is not proposed to be a major
centralised organisation. It is envisaged as a small core of Enhance staff with
a distributed support structure using the best personnel in partners and
licensed associates.

THE ENHANCE MARKET PLACE TODAY
Investment in the development of lifestyle drugs over the last ten years has
exceeded $20 billion and yet relatively few products have come to market and in
many conditions listed above there are no imminent additions to the presently
available treatments.

The objective for the lifestyle sector of the pharmaceutical industry is to
address conditions that were previously ignored or poorly understood because of
their sensitive nature. As these needs are met the patient will have an
increasing degree of choice for treatment of conditions that, because of the
impact upon their lifestyle they believe to be serious. The added benefit to the

<PAGE>

physician will be a wider choice of treatments while in some conditions
treatments will become available over the counter for the first time. The
ultimate benefit will be the improvement of quality of life allowing individuals
to live and work normally having recognised and dealt with their condition.

PRODUCT SCIENCE & STATUS
LIF 301: SEXUAL DYSFUNCTION THERAPY
The recent global success of Viagra has focused attention on one aspect of this
problem area but a second issue that of male premature ejaculation has been
recognised as the next major condition that needs attention. Like erectile
dysfunction there is a degree of recognition of the problem in the patient body
which has raised the issue with the medical profession but there are a huge
proportion of males who will not find it acceptable to be open about this issue
even with their own doctor. The table below demonstrates the comparable scale of
the market and the benefit of a recognisable easily delivered product in winning
the major market share for Viagra.

While it is recognised there is considerable influence from the psychology of
this condition recent research has increasingly recognised there are physical
symptoms that can be treated. Work has included the use of SSRI
anti-depressants, recognised as reducing sexual drive in both sexes and other
treatments that have indicated controls of the physical condition are
potentially effective.

Part of the problem is the result of the build up of smooth muscle tissue in the
area of the penis controlling ejaculation such control is reduced or lost. If
the development of the smooth muscle tissue is broken down and indeed stopped by
a drug intervention then the performance of the control muscles improves.
However the precise mechanism of operation for the drug in the patient's system
is yet to be fully understood following successful pre-clinical trials.

Pre clinical trials with the Enhance product on a sample of six patients, 4
affected and 2 controls demonstrated a 100% experience of improvement of the 4
affected individuals with no toxicity found.

The product is based upon analgesic science and has been developed by a research
house in the UK into a low dosage orally delivered drug. The initial formulation
will therefore be derived from a currently available drug making progress to
market relatively quick. Meanwhile the next stage of development is to take the
newly created analogue of this product forward as it has further unique
properties that strengthen our ownership and control. In the mean time the
product will be delivered as a pill which during trial demonstrated a quick
effect, less than 30 minutes, making it convenient to take when required.

Testing for the next Phase I / II trials for this product has been planned in
Holland and is reflected in the acquisition agreement Enhance has negotiated for
the product and its future developments. These trials can be implemented within
3 months and the progress to completion of Phase II within 18 months is a
realistic prospect. The development of the analogue is expected to be a three
year plus programme form this point forward.

Enhance foresee a major partner for this product but will build desire and value
in the product over the trials before initiating discussions with suitable
targets.

LIF 236: ANTI AGEING
This is a condition affecting everyone and comprises of a number of indications
that can be addressed in treatment regimes. It is also a condition where people
are increasingly seeking answers to the maintenance of their youth and fitness
in a world where the baby booms of the 1960's are coming through as the grey
boom of the new century combined with a previously unseen affluence in this
sector of the population.

The primary indications that accompany ageing and indeed premature ageing
include, loss of sleep, skin ageing, loss of hair condition, increase of weight
thickening around the middle, increasing risk linked to this of both
hypertension and diabetes and memory loss. It is recognised widely that a
substantial contributor to these conditions generates from the bodies natural
ability to produce cortisol. Cortisol is created as a natural reaction to our
diurnal cycle giving the signal for that early morning boost of energy the body
needs to cope with the day ahead and again when faced with stressful
circumstances. It is driven by the HPA axis. That is to say the hypothalamus
<PAGE>

provides the brain signals to react, to the pituitary glands firstly, which in
turn trigger production of cortisol from the adrenal glands. In turn the level
of cortisol released is monitored by hypothalamus to an acceptable level for the
individual's system at which point it stimulates the production of the "off
switch" compound ketotrilostane. This is a naturally produced product in a group
known as 3beta HSD inhibitors. In the ageing body this cycle of cortisol
production and shut down is gradually moving out of synchronisation with the
diurnal cycle and generates the conditions where the indications of ageing can
begin to thrive.

Initial trials with a low dosage have proven successful in controlling cortisol
production. It is envisaged trials will be run with a 5mg dose initially.
Meanwhile Enhance will be developing exclusively the synthetic version of the
natural ketotrilostane which is two and a half times more active than the base
compound that it was derived from. Both will be developed for oral delivery. The
source of these products is the same development house from the UK.

Initial trial results for the base compound related to the effects of Cushing's
syndrome show that we can expect to see benefits for patients suffering the
ageing conditions in each of the major indications. In addition we foresee
opportunity for the product as an enhancer for memory and potentially therefore
having a place in early stage Alzheimer treatment.

LIF 303: ANTI-CELLULITE
The effect of cellulite is predominant in women where over 40% of women over the
age of 35 have the condition. Cellulite forms as a result of the normally
lamellar layer of collagen, adipose tissue, present under our skin deforms into
a downward rooting structure that grows down in to the reticular dermis. The

condition is rarer in men as this adipose tissue forms a smooth layer in the
male while being broken up in the female. The degree of this broken layer of
adipose tissue beneath the surface varies between individuals and over the
commonly affected areas on any individual. The common visual symptom is an
orange peel appearance to the skin particularly on the thighs and buttocks,
caused by the skin surface being pulled down by the deformations underneath.

It is a condition that is high profile and has attracted many cosmetic and
herbal creams and treatments, few of which have been medically tested and
non-proven1. Many of these creams seem to rely upon caffeine as the active
ingredient while there other products have tried retinol and conjugated linoleic
acid. There is no prescription treatment for the solution and little work going
on to medically research and test alternatives to the cosmetic offerings to
date. However the market spending on these products and surgical solutions is
substantial and the profile of the problem is rated extremely high amongst the
female population.

Early stages of clinical testing with a low dose procollagenase product derived
from an existing marketed drug used in the treatment of endometriosis have
demonstrated an ability to reduce the problem of adipose tissue deformation
significantly2. Enhance has access to this product along with the opportunity to
develop a second stage product with low risk of side effect which is at the
patent applied for stage of development.

Trials on a larger scale, between 100 and 150 patients, are needed to test the
dosage and risk of androgenic side effects at that level with a view to creating
a low dose prescription product for treatment of severe cases of cellulite. This
can be developed to market and a positive reputation built over the next two
years while the new compound, known to be free of the side effects of the first,
will be developed. Both drugs will be developed for both oral and transdermal
application with a view to the second stage product being available over the
counter. Partners for early stage trials and manufacture have been selected but
as yet trials have not been planned out.

LIF 316: IN-VITRO FERTILISATION
While the initial focus for this development programme is meeting need in the
invitro fertilisation laboratory the exciting lifestyle developments will be
derived from this work in due course. The product group consists of three
products, one a natural product of the human body and the other two new
compounds developed by specialists in this field. Enhance has the relationship
of licensing and funding the development of the product group in conjunction
with a high profile UK research and learning group.


<PAGE>

Present test tube technology for the in-vitro fertilisation process relies upon
the sperm and egg being manipulated under controlled conditions in the
laboratory and includes the use of a toxic carrier for the process. The Enhance
technology is able to replace this carrier with a natural non-toxic alternative
where controls on the motility and capacitance of the sperm can be closely
maintained. The driver that generates motility is based upon the natural hormone
angiotensin while the two further compounds have demonstrated the ability to
stop sperm in suspended animation allowing them to be rejuvenated with no loss
in capacitance or acrosomal performance. This is man exciting step forward for
the in-vitro fertilisation process itself but has enormous potential
significance to the lifestyle fertility area.

The ability to generate increased motility ion the sperm provides the basis for
a naturally produced product to be administered for the increase of male sperm
motility, one of the common causes of male infertility. Potentially this can be
a cream, pessary or possibly oral delivery and the resulting effect is fast. The
counterbalance of the increase in motility is a natural compound that can hold
the male sperm in suspended animation providing the potential for a male
contraceptive administered orally or possibly as a pessary to the female
partner. At this stage the lab results leave Enhance to manufacture suitable
delivery systems for these compounds and to initiate field trialling. This will
continue with ongoing support from the research institution from which the
technology is sourced. For both the second stage products substantial numbers
will need to be field tested, with an initial 100 patients rising to 1000.

For the IVF product there is the need to establish manufacture, possibly
including a delivery system to make the product more attractive and unique.

RESULTS OF OPERATIONS

The Company derived no revenues during the fiscal year to January 31, 2003, and
had a net loss of $608,063, which is attributable to the acquisition of Enhance
Lifesciences Limited, and the expenses from that company since the acquisition
closing date of 17th December 2002 to January 31, 2003. The Company has an
accumulative net loss from inception to January 31, 2003 of $837,635. This
figure will increase as the operations of Enhance Lifesciences Limited are
integrated into the company until such time that the Company's products are
commercialized and ultimately revenue and net income are achieved.

LIQUIDITY

The Company's viability as a going concern is dependent upon raising additional
capital, and ultimately, having net income.

The Company's limited operating history, including its losses and no revenues,
primarily reflect the operations of its early stage.

The Company requires additional capital principally to meet its costs for the
implementation of its business plan, for general and administrative expenses and
to fund costs associated with the development of its products. It is not
anticipated that the Company will be able to meet its financial obligations
through internal net revenue in the foreseeable future.

SUBSEQUENT EVENTS

On April 29th, 2003 all of the Company's issued and outstanding stock was
acquired by Becor Communications Inc, now known as Enhance Biotech, Inc. Enhance
Biotech Inc's common stock trades on the OTCBB under the symbol EBOI. Upon the
closing of the acquisition Enhance Biotech Inc adopted the business plan of
Enhance Lifesciences Inc.


<PAGE>


ITEM 7. FINANCIAL STATEMENTS

TO THE BOARD OF DIRECTORS AND STOCKHOLDERS OF ENHANCE LIFESCIENCES, INC

I have audited the accompanying Balance Sheet of Enhance Lifesciences Inc., (a
development stage company) as of January 31, 2003 and the related statements of
loss, cash flows and stockholders equity (deficiency), for the year ended
January 31, 2003 and for the period from December 31, 1996 (inception) to
January 31, 2003. These financial statements are the responsibility of the
Company's management. My responsibility is to express an opinion on these
financial statements based upon my audit.

I conducted my audit in accordance with generally accepted auditing standards.
Those standards require that I plan and perform the audit to obtain reasonable
assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
I believe that my audit provides a reasonable basis for my opinion.

In my opinion the financial statements referred to above represent fairly, in
all material respects, the financial position of Enhance Lifesciences, Inc., as
of January 31, 2003 and the results of its operations and its cash flows for the
year ended January, 31, 2003 and for the period from December 31, 1996
(inception) to January 31, 2003 in conformity with generally accepted accounting
principles.

The accompanying financial statements have been prepared assuming that the
Company will continue as a going concern. As discussed in Note 2 to the
financial statements, the Company has losses from operations and a net capital
deficiency, which raise substantial doubt about its ability to continue as a
going concern. Management plans regarding those matter also are described in
Note 2 and 3. The financial statements do not include any adjustments that might
result from the outcome from this uncertainty.

F E Hanson Ltd
Arlington, VA
June 12, 2003


<PAGE>


                            ENHANCE LIFESCIENCES, INC
                          (A Development Stage Company)
                                  BALANCE SHEET



                                                      Jan, 31      Jan, 31
                                                       2002          2003
                                                     ---------    ---------

ASSETS :

Current Assets:
   Other Current Assets                                      3            3
   Investments in Affiliated Companies                       0            0
   Intangibile Assets                                        0            0
                                                     ---------    ---------
TOTAL ASSETS:                                        $       3    $       3
                                                     ---------    ---------


LIABILITIES AND STOCKHOLDER'S EQUITY

Current Liabilities:
   Accounts Payable                                  $ 227,566    $ 872,714
   Accrued Expenses and Other Liabilities                    0            0
   Other Current Liabilities                                 0            0

                                                     ---------    ---------
Total Current Liabilities                            $ 227,566    $ 872,714

Stockholder's Equity:
   Common Stock                                              3       20,000
   25,000,000 shares authorized at .001 per share,
   20,000,000 Outstanding
   Accumulated Other Comprehensive Income/Loss           2,006     (126,726)
  Additional Paid in Capital                                 0       71,650
  Accumulated Deficit                                 (229,572)    (837,635)
                                                     ---------    ---------

Total Stockholder's Equity                           $(227,563)   $(872,711)
   TOTAL LIABILITIES AND STOCKHOLDER'S
   EQUITY                                                    3    $       3

                                                     ---------    ---------



The accompanying notes are an integral part of these financial statements.



<PAGE>



                           ENHANCE LIFESCIENCES, INC.
                          (A Development Stage Company)
                           Condensed Statement of Loss
                     For the Year Ended January 31, 2003 And
               From April 24, 1997 (Inception) To January 31, 2003



                                For the Year    For the Year          From
                                   Ended           Ended           Inception to
                                Jan, 31, 2003   Jan, 31,2002      Jan, 31, 2003
                                -------------   ------------      -------------

Total Revenues :                $         0     $         0       $         0
                                -----------     -----------       -----------

Operating Expenses:

General & Administrative            303,063         204,572           507,635
Other Start up Costs                      0               0                 0
Research & Development              305,000          25,000           330,000
Depreciation & Amortization               0               0                 0
                                -----------     -----------       -----------
Total Operating Expenses            608,063         229,572           837,635
                                -----------     -----------       -----------
Net Loss                        $  (608,063)    $  (229,572)      $  (837,635)
                                -----------     -----------       -----------
Net Loss Per Share              $    (0.001)    $  (114,786)      $    (1.005)
                                -----------     -----------       -----------
Weighted Average Number
Of Shares Outstanding            20,000,000               2          833,334
                                -----------     -----------       -----------



The accompanying notes are an integral part of these financial statements.



<PAGE>



                            ENHANCE LIFESCIENCES, INC
                          (A Development Stage Company)
                             STATEMENT OF CASH FLOWS
                  FOR THE YEAR ENDED JANUARY 31, 2003 AND 2002
           AND FROM DECEMBER 31, 1996 (INCEPTION) TO JANUARY, 31, 2003


<TABLE>
<CAPTION>

                                             For the Year      For the Year        From
                                                 Ended            Ended         Inception to
                                             Jan 31, 2003      Jan 31, 2002    Jan, 31, 2003
                                             ------------      ------------    -------------
<S>                                            <C>              <C>               <C>
Net Loss                                       $(608,063)       $(229,572)        $(837,635)
                                               ---------        ---------         ---------

Adjustments to Reconcile Net
Loss to Net Cash used in
Operating Activities :
Decrease/Increase
In Accrued Expenses                                    0                0                 0
Net Decrease/Increase
Assets/Liabilities
Accounts Payable                                 645,148          227,566           872,714

                                               ---------        ---------         ---------
Net Adjustments                                  645,148          227,566           872,714
Net Cash Used in
Operating Activities                              37,085           (2,006)           35,079
Cash Flows From
Financing Activities                                   0                0                 0
                                               ---------        ---------         ---------
Effect of Exchange Rate Changes                  (37,085)           2,006            35,079

Net Change in Cash                                     0                0                 0
Cash at Beginning of Period                            0                0                 0
Cash at End of Period                                  0                0                 0

Supplemental disclosure of
Cash Flow information
Interest                                               0                0                 0
Taxes                                                  0                0                 0

Non Cash Investing & Financing Activities
Issuance Common Stock                             17,000                0                 3
</TABLE>


The accompanying notes are an integral part of these financial statements.



<PAGE>



ENHANCE LIFESCIENCES, INC

                          (A Development Stage Company)
   Statement of Shareholder's Equity(Deficit) From April 24, 1997 (Inception)
                              To January 31, 2003


<TABLE>
<CAPTION>

                                                                                    Total
                                  Common Stock Issued              Additional       Accumulated          Shareholder's
                                  Shares        Par Value          Paid in Cap      Deficit              Equity
                            ---------------------------------------------------------------------------------------------
<S>                                <C>            <C>                 <C>          <C>                 <C>
Issuance of
2
Shares
April 24,1997                          2              $3                  0           $       0           $           3
Net Loss
For the Period from
Inception to
Jan 31, 2001                           0               0                  0                   0                       0

                            ---------------------------------------------------------------------------------------------
Balance
Jan 31, 2001                           2         $     3                  0                   0                       3

Issuance of
Shares Jan 31 2002                     0         $     0                  0                    0                      0
Net Loss for
The Year Ended
Jan 31, 2002                           0               0                  0             (229,572)              (229,569)

                            ---------------------------------------------------------------------------------------------
Balance
Jan 31 2002                            2         $     3           $      0          $  (229,572)         $    (229,569)
Issuance of Shares
December 17 2002              19,999,998         $20,000           $ 71,650                    0                 91,647
Net Loss
For the Year
Ended
Jan 31, 2003                           0               0                               (608,063)               (608,063)

                            ---------------------------------------------------------------------------------------------
Balance
Jan 31, 2003                   20,000,000       $20,000           $71,650           $  (837,635)          $    (745,985)
Net Loss
</TABLE>


The accompanying notes are an integral part of these financial statements.


                           ENHANCE LIFESCIENCES, INC.
                          (A Development Stage Company)

                          NOTES TO FINANCIAL STATEMENTS
                                January 31, 2003

NOTE 1 - NATURE OF BUSINESS AND SIGNIFICANT ACCOUNTING PRINCIPLES

A. DESCRIPTION OF PROPERTY: Enhance Lifesciences, Inc. ("the Company") is a
for-profit corporation incorporated under the laws of the State of Delaware on
December 31, 1996. Enhance Lifesciences, Inc. provide objective is to engage in
the business of developing pharmaceutical products within the lifestyle drug
sector.

B. BASIS OF PRESENTATION : Financial Statements are prepared on the accrual
basis of accounting. Accordingly revenue is recognized when earned and expenses
when incurred.

C. USE OF ESTIMATES : The preparation of financial statements in conformity with
generally accepted accounting principles requires management to make estimates
and assumption that affect certain reported amounts and disclosures.
Accordingly, actual results could differ from these estimates. Significant
estimates in the financial statements include the assumption that the Company
will continue as a going concern. See Note 3.

<PAGE>


NOTE 2 - EARNINGS PER SHARE



                          For the Year            From Inception
                             Ended                     Ended
                         January 31, 2003         January 31, 2003
                         ----------------         ----------------
Net Loss per share          $(0.0001)               $ (114,786)


NOTE 3 - LIQUIDITY

The Company's viability as a going concern is dependent upon raising additional
capital, and ultimately, having net income. The Company's limited operating
history, including its losses and no revenue, primarily reflect the operations
of its early stage. As a result, the Company had from time of Inception to
January 31, 2003 no revenue and a net loss from operations of $837,635. As of
January 31, 2003, the Company had a net capital deficiency of $872,711.

The Company requires additional capital principally to meet its costs for the
implementation of its Business plan, for general and administrative expenses and
to fund costs associated with the start up of its pharmaceutical products. It is
not anticipated that the Company will be able to meet its financial obligations
through internal net revenue in the foreseeable future. Enhance Lifesciences,
Inc does not have a working capital line of credit with any financial
institution. Therefore, future sources of liquidity will be limited to the
Company's ability to obtain additional debt or equity funding.

NOTE 4 - CHANGE OF NAME

On June 25th, 2002 changes its name from European Technology Enterprises Inc to
Enhance Lifesciences Inc.

NOTE 5 - STOCK SPLIT

On December 17th 2002, a reverse stock split of one to two occurred.

NOTE 6 - ACQUISITION

On September 10th 2002, an acquisition agreement was signed where the Company
(ETE) would acquire Enhance Lifesciences Ltd, UK (ELSI). On December 17th 2002
the acquisition was completed where the Company issued 17,000,000 shares at a
par value of $0.001. The acquisition is considered to be a reverse merger which
has the following consequences. The net assets of ELSI have been brought forward
at their carrying value and there has been no change in basis or recognition of
goodwill in connection with the merger. The accumulated deficit of ELSI has been
brought forward and the accumulated deficit of ETE eliminated on consolidation.
The common stock and the additional paid in capital have been retroactively
restated.
The pre-merger results of ELSL are now the historical results of operations of
the merged entity.

NOTE 7 - LEGAL PROCEEDINGS

As of the date of this report there are no judgements or pending litigation.


<PAGE>


ITEM 8. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURE

There have been no changes in, or disagreements with, accountants on accounting
and financial disclosure matters.

                                    PART III

ITEM 9. DIRECTORS AND EXECUTIVE OFFICERS



                           Position(s) Held and
Name                 Age    Duration of Service     Family Relation
----------------     ---    -------------------     ---------------
Christopher Every     50    President and Director        None
Lee Cole              42    Secretary-Treasurer
                            and Director                  None
Roger Holdom          37    Director                      None



All directors hold office until the next annual meeting of stockholders and
until their successors have been duly elected and qualified. There are no
agreements with respects to the election of directors. The old directors of the
company resigned their positions on 17th December 2002 when the acquisition to
acquire Enhance Lifesciences Limited completed.

Set forth below is certain biographical information regarding the Company's
executive officers and directors:

CHRISTOPHER EVERY. Mr. Every is 50 years old. He career in sales and marketing,
predominantly in the industrial and pharmaceutical areas, lead to his holding
senior board positions. His sales and marketing career includes various
positions with Wiggins Teape, National Starch Corporation of America (a Unilever
subsidiary group), and General Electric Company. As a result of this experience
Mr. Every developed a wide-ranging knowledge of large corporate organizations in
the range of major "blue chip" industries and the broadest possible array of
businesses. Since 1985 Mr. Every has worked for Electrolux, Entre Computers,
Promo Ticket Promotions Ltd and Ashridge Management College. Mr. Every is also a
former senior Managing Director with Williams Holdings PLC. He has also provided
consultant services to major companies and government bodies in the UK and
Europe, predominately in regard to strategic management. The clients which Mr.
Every has developed over the last ten years include, Alpha Airport Services,
Eften Europa, NATO (Luxembourg), CIPAL Belgium, Antwerp Regional Government tax
offices, and Associated Tyre Services, Gieves & Hawkes, East Midlands
Electricity, Altro Floors, Gardner Merchant, Richard Ellis & Quentin, Micro
Warehouses Ltd, Powergen plc and TXU Energi.

LEE COLE. Mr. Cole is 42 years old and has extensive experience in rapid growth
companies and executing acquisition strategies. Since January 1995, Mr.Cole has
been a principal of Tech Capital Group, a technology consulting firm that has
private and public information and healthcare technology companies as clients.
Additionally, in 1997, Mr. Cole was the co-founder of a public biotechnology
company, Bioenvision, Inc.

ROGER HOLDOM. Mr. Holdom is 37 years of age and has over 18 years experience in
marketing at senior management level in the Pharmaceutical, Broadcasting and
Technology sectors. From 1997 to 1999 Mr. Holdom was the Head of Network
Development Europe at Discovery Communications where he was responsible for the
negotiation, management and administration of the European and African
distribution contracts for Discovery's global satellite and cable channel. Prior
to 1997, Mr Holdom was a senior marketing director at the BBC.
<PAGE>

To the knowledge of management, during the past five years, no present or former
director or executive officer of the Company:

(1) filed a petition under the federal bankruptcy laws or any state insolvency
law, nor had a receiver, fiscal agent or similar officer appointed by a court
for the business or present of such a person, or any partnership in which he was
a general partner at or within two years before the time of such filing, or any
corporation or business association of which he was an executive officer within
two years before the time of such filing;

(2) was convicted in a criminal proceeding or named subject of a pending
criminal proceeding (excluding traffic violations and other minor offenses);

(3) was the subject of any order, judgment or decree, not subsequently reversed,
suspended or vacated, of any court of competent jurisdiction, permanently or
temporarily enjoining him form or otherwise limiting, the following activities:
(i) acting as a futures commission merchant, introducing broker, commodity
trading advisor, commodity pool operator, floor broker, leverage transaction
merchant, associated person of any of the foregoing, or as an investment
advisor, underwriter, broker or dealer in securities, or as an affiliated
person, director of any investment company, or engaging in or continuing any
conduct or practice in connection with such activity;


<PAGE>


(ii) engaging in any type of business practice; or (iii) engaging in any
activity in connection with the purchase or sale of any security or commodity or
in connection with any violation of federal or state securities laws or federal
commodity laws;

(4) was the subject of any order, judgment, or decree, not subsequently
reversed, suspended, or vacated, of any federal or state authority barring,
suspending, or otherwise limiting for more than 60 days the right of such person
to engage in any activity described above under this Item, or to be associated
with persons engaged in any such activity;

(5) was found by a court of competent jurisdiction in a civil action or by the
Securities and Exchange Commission to have violated any federal or state
securities law, and the judgment in subsequently reversed, suspended, or vacate;

(6) was found by a court of competent jurisdiction in a civil action or by the
Commodity Futures Trading Commission to have violated any federal commodities
law, and the judgment in such civil action or finding by the Commodity Futures
Trading Commission has not been subsequently reversed, suspended or vacated.

The Company's common stock has not been previously registered.

ITEM 10. EXECUTIVE COMPENSATION

SUMMARY

The Company has not had a bonus, profit sharing, or deferred compensation plan
for the benefit of its employees, officers or directors. The Company has not
paid any salaries or other compensation to its officers, directors or employees
for the year ended January 31, 2002, nor at any of its officers, directors or
any other persons and no such agreements are anticipated in the immediate
future. It is intended that the Company's directors will forego any compensation
until such time as an accusation or merger can be accomplished and will strive
to have the business opportunity provide their remuneration. As of the date
hereof, no person has accrued any compensation from the Company.

The payment of the directors compensation by any target company will not be a
criteria of consideration in the event the Company consummates an acquisition,
alliance, merger or business transaction with another entity.

COMPENSATION TABLE: None; no form of compensation was paid to any officer or
director at any time during the last two fiscal years.

CASH COMPENSATION
There was no cash compensation paid to any director or executive officer of the
Company during the two fiscal years ended January 31, 2003

BONUSES AND DEFERRED COMPENSATION: NONE.

COMPENSATION PURSUANT TO PLANS: NONE.

PENSION TABLE: NONE.

OTHER COMPENSATION: NONE.

COMPENSATION OF DIRECTORS: NONE.

TERMINATION OF EMPLOYMENT AND CHANGE OF CONTROL ARRANGEMENT:
There are no compensatory plans or arrangements of any kind, including payments
to be received from the Company, with respect to any person which would in any
way result in payments to any such person because of his or her resignation,
retirement, or other termination of such person's employment with the Company or
its subsidiaries, or any change in control of the Company, or a change in the
<PAGE>

person's responsibilities following a change in control of the Company.


<PAGE>


ITEM 11. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The following table sets forth the information, to the best knowledge of the
Company as of June 19th, 2003, with respect to each person known by the Company
to own beneficially more than 5% of the Company's outstanding common stock, each
director of the Company and all directors and officers of the Company as a
group.



Name and Address of      Amount and Nature of            Percent
Beneficial Owner         Beneficial Ownership            of Class
----------------         --------------------            --------

Enhance Biotech Inc         20,000,000                    100%


1285 Avenue of the Americas
35th Floor
New York, NY, 10019

The Company has been advised that the persons listed above have sole voting,
investment, and dispositive power over the shares indicated above. Percent of
Class (third column above) is based on 20,000,000 shares of common stock
outstanding as of 19th June 2003.

The Directors of the Company are also the Directors of the shareholder listed
above.



<PAGE>



ITEM 12. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS WITH MANAGEMENT AND
OTHERS.

To the best of Management's knowledge, during the fiscal year ended January 31,
2003, there were no material transactions, or series of similar transactions,
since the beginning the Company's last fiscal year, or any currently proposed
transactions, or series of similar transactions, to which the Company was or is
to be a party, in which the amount involved exceeds $60,000, and in which any
director or executive officer, or any security holder who is known by the
Company's common stock, or any member of the immediate family of any of the
foregoing persons, has an interest.

CERTAIN BUSINESS RELATIONSHIPS:

During the fiscal year ended January 2003, there were no material transactions
between the Company and its management.

INDEBTEDNESS OF MANAGEMENT:
To the best of Management's knowledge, during the fiscal year ended January 2003
there were no material transactions, or series of similar transactions, since
the beginning of the Company's last fiscal year, or any currently proposed
transactions, or series of similar transactions, to which the Company was or is
to be a party, in which the amount involved exceeds $60,000, and in which any
director or executive officer, or any security holder who is known by the
Company to own of record or beneficially more than 5% of any class of the
company's common stock, or any member of the immediate family of any of the
foregoing persons, has an interest.

TRANSACTIONS WITH PROMOTERS:
To the best Knowledge of management, no such transactions exist.

ITEM 13. FINANCIAL STATEMENTS, EXHIBITS AND REPORTS ON FORM 8-K

(A) FINANCIAL STATEMENTS
The Following financial statements are filed as part of this registration
statement:

Balance Sheet
Statement of Loss
Statement of Cash Flows
Statement of Shareholders' Equity (Deficit) Selected Financial Data

(B) EXHIBITS AND INDEX OF EXHIBITS
The following exhibits are included in Item 13(c). Other exhibits have been
omitted since the required information is not applicable to the registrant.

(C) REPORTS ON FORM 8-K No The Company filed a Form 8K announcing the signing of
the transaction with Enhance Lifesciences Limited on 19th September 2002 and
also filed a Form 8K/A on 7th January 2003 announcing that the transaction had
closed, whereby a copy of the acquisition agreement was filed which is
incorporated by reference.

SIGNATURES

Pursuant to the requirements of Section 12 of the Securities Exchange Act of
1934, the registrant has duly caused this registration statement to be signed on
its behalf by the undersigned, thereunto duly authorized.

ENHANCE LIFESCIENCES, INC.
(Registrant)

Date: November 17, 2003





By: /s/ Christopher Every
    -------------------
    President